Market Overview

UPDATE: Piper Jaffray Raises PT to $69 on Jazz Pharmaceuticals; Growth Visibility is Solid

Share:
Related JAZZ
Heavy News Day For Several Biotech Stocks
8 Stories JP Morgan Is Watching Today
Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog (Zacks)

Piper Jaffray maintained Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Overweight and raises the price target from $65.00 to $69.00.

Piper Jaffray commented, "JAZZ remains our top mid-cap spec pharma pick for 2013, with strong visibility on consistent long-term double-digit EPS growth, high barriers for potential Xyrem generics, all in the context of a 2013 P/E of only 10x. Further, with JAZZ still committed to additional acquisitions of commercial or near-commercial assets, and a strong balance sheet ($387M in cash at YE2012) and potentially more than $400M in operating cash flow generation in 2013, the company is well positioned to execute on a transaction that provides near-term earnings accretion and further revenue diversification in our view."

Jazz Pharmaceuticals closed at $56.83 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Feb 2015BMO CapitalInitiates Coverage onOutperform
Nov 2014CitigroupMaintainsBuy
Nov 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (JAZZ)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→